(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 4 782 065 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
**Corrected version no 1 (W1 A2)**
**Corrections, see**
**Bibliography INID code(s) 71**

(48) Corrigendum issued on:
**21.10.2026 Bulletin 2026/43**

(43) Date of publication:
**29.07.2026 Bulletin 2026/31**

(21) Application number: **26170374.8**

(22) Date of filing: **11.09.2020**

(51) International Patent Classification (IPC):
***A61K 31/506*** *(2006.01)* ***A61P 35/00*** *(2006.01)*

(52) Cooperative Patent Classification (CPC):
(C-Sets available)
**A61K 31/506; A61P 35/00** (Cont.)

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(30) Priority: **13.09.2019 PCT/EP2019/074565**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
**20772249.7 / 4 028 010**

(71) Applicant: **The Institute of Cancer Research: Royal Cancer Hospital**
**London SW7 3RP (GB)**

(72) Inventor: **BANERJI, Udai**
**London, SW7 3RP (GB)**

(74) Representative: **Hoffmann Eitle**
**Patent- und Rechtsanwälte PartmbB**
**Arabellastraße 30**
**81925 München (DE)**

Remarks:
•This application was filed on 02.04.2026 as a divisional application to the application mentioned under INID code 62.
•Claims filed after the date of filing/ after the date of receipt of the divisional application (Rule 68(4) EPC)

(54) **THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE**

(57) This invention relates to methods comprising administering a FAK inhibitor (*e.g.*, VS-6063) in combination with a dual RAF/MEK inhibitor (*e.g.*, CH5126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.

EP 4 782 065 A8

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets
**A61K 31/506, A61K 2300/00**